Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trialJean‐Michel Molina, Juergen Rockstroh, Nina Weis et al.|The Lancet HIV|2018Cited by 145